Abstract
HTRS2023.P2.18 Pediatric persons with hemophilia A on EHL-FVIII or emicizumab prophylaxis require iron therapy despite low annualized bleeding rate
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Research and Practice in Thrombosis and Haemostasis
Paper Title
Journal
Date
